Cargando…

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir

BACKGROUND: Congenital CMV (cCMV) is associated with sensorineural hearing loss and neurodevelopmental disabilities. Infants with symptomatic cCMV infection benefit from 6 months of oral valganciclovir (vGCV) therapy. Neutropenia, thrombocytopenia, and hepatotoxicity are adverse effects vGCV, for wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murtagh, Kathleen, Toia, Jacquie, Scardina, Tonya, Rowley, Anne H, Mithal, Leena B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776892/ http://dx.doi.org/10.1093/ofid/ofaa439.1332

Ejemplares similares

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection
por: Ohyama, Shohei, et al.
Publicado: (2019)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Incidence of UL97 Resistance Mutations in Infants with Congenital Cytomegalovirus Disease Receiving 6 Months of Oral Valganciclovir Therapy
por: James, Scott H, et al.
Publicado: (2017)

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment
por: Torii, Yuka, et al.
Publicado: (2023)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Cavity for 114.6 MHz
por: Croizat, M, et al.
Publicado: (1984)

569. A Multidisciplinary Approach to the Pre-evaluation Process of Pediatric Solid Organ Transplant Patients
por: Toia, Jacquie, et al.
Publicado: (2020)

Long-Term Clinical, Audiological, Visual, Neurocognitive and Behavioral Outcome in Children With Symptomatic and Asymptomatic Congenital Cytomegalovirus Infection Treated With Valganciclovir
por: Turriziani Colonna, Arianna, et al.
Publicado: (2020)

1146. Lactococcus species Catheter-Related Bloodstream Infections in Pediatrics: A Case Series
por: Firmani, Sarah E, et al.
Publicado: (2021)

Efficacy and safety of valganciclovir in patients with symptomatic congenital cytomegalovirus disease: Study Protocol Clinical Trial (SPIRIT Compliant)
por: Morioka, Ichiro, et al.
Publicado: (2020)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan
por: Morioka, Ichiro, et al.
Publicado: (2022)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Case report: severe cytomegalovirus primary infection in an immunocompetent adult with disseminated intravascular coagulation treated with valganciclovir
por: Müller, Niklas F., et al.
Publicado: (2016)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature
por: Pata, Davide, et al.
Publicado: (2023)

Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and Efficacy
por: Kalil, Andre C., et al.
Publicado: (2009)

Long-term results of oral valganciclovir for treatment of anterior segment inflammation secondary to cytomegalovirus infection
por: Wong, Victoria WY, et al.
Publicado: (2012)

1380. Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-)
por: Roumpz, Caroline G, et al.
Publicado: (2021)

1146. Real-World Experience Highlighting Tocilizumab Use in the Treatment of COVID-19
por: Maguire, Christina, et al.
Publicado: (2022)

Epidemiology of middle ear and mastoid cholesteatomas. Study of 1146 cases
por: de Aquino, Jose Evandro Andrade Prudente, et al.
Publicado: (2015)

P1146: TRANSFUSION NEEDS AFTER CD19 CAR T-CELLS FOR LARGE B-CELL LYMPHOMA: PREDICTIVE FACTORS AND IMPACT ON OUTCOME. A DESCAR-T STUDY.
por: Vic, Samuel, et al.
Publicado: (2023)

Isolated congenital asplenia: An overlooked cause of thrombocytosis
por: Borsani, Oscar, et al.
Publicado: (2022)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Treatment of unilateral zone I cytomegalovirus retinitis in acute lymphoblastic leukemia with oral valganciclovir and intravitreal ganciclovir
por: Tripathy, Koushik, et al.
Publicado: (2017)

1146. Antibiotic Use in Infants Predicts Asthma Rate in Children 1–4 years at Fine Geographic Scale
por: Mamun, Abdullah A, et al.
Publicado: (2019)

Valganciclovir: Leucopenia: case report
Publicado: (2021)

1146. Effectiveness of Ultraviolet Irradiation on Candida auris: A Laboratory Study
por: Garmon, Gennifer, et al.
Publicado: (2018)

Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Barkam, Corinna, et al.
Publicado: (2012)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

Non-healing Vulval Ulcer in an Immunocompromised Female due to Concurrent Herpes Simplex Virus and Cytomegalovirus Co-infection Treated Effectively with Valganciclovir
por: Sinha, Preema, et al.
Publicado: (2020)

P1336: ANTIVIRAL EXPOSURE TO GANCICLOVIR AND VALGANCICLOVIR IS NOT ASSOCIATED WITH INCREASED INCIDENCE OF RELAPSE OR SECONDARY MALIGNANCIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Duarte, D., et al.
Publicado: (2022)

Thrombocytosis
por: Vitiritti, M
Publicado: (2010)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6l5hbov2vj32kkplurrarro8o8